Barbosa Izabela G, Miranda Aline S, Berk Michael, Teixeira Antonio L
Departamento de Psiquiatria, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil.
Programa de Pós-Graduação em Neurociências, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
Expert Rev Neurother. 2025 Jan;25(1):85-99. doi: 10.1080/14737175.2024.2438646. Epub 2024 Dec 8.
There is a growing body of evidence implicating gut-brain axis dysfunction in the pathophysiology of mood disorders. Accordingly, gut microbiota has become a promising target for the development of biomarkers and novel therapeutics for bipolar and depressive disorders.
We describe the observed changes in the gut microbiota of patients with mood disorders and discuss the available studies assessing microbiota-based strategies for their treatment.
Microbiota-targeted interventions, such as symbiotics, prebiotics, paraprobiotics, and fecal microbiota transplants seem to attenuate the severity of depressive symptoms. The available results must be seen as preliminary and need to be replicated and/or confirmed in larger and independent studies, also considering the pathophysiological and clinical heterogeneity of mood disorders.
越来越多的证据表明肠-脑轴功能障碍与情绪障碍的病理生理学有关。因此，肠道微生物群已成为开发双相情感障碍和抑郁症生物标志物及新型治疗方法的一个有前景的靶点。
我们描述了情绪障碍患者肠道微生物群的观察变化，并讨论了评估基于微生物群的治疗策略的现有研究。
以微生物群为靶点的干预措施，如共生菌、益生元、副益生菌和粪便微生物群移植，似乎可以减轻抑郁症状的严重程度。现有结果必须被视为初步的，需要在更大规模的独立研究中进行重复和/或验证，同时也要考虑情绪障碍的病理生理和临床异质性。
